Skip to Main Content

Try STAT+ TODAY

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Morning Rounds Newsletter

Pharmalot Ed Silverman

STAT Plus: Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

The U.S. solicitor general urged the Supreme Court to review a controversy over generic drug access and "skinny labels" for medicines.

Pharma John Wilkerson

STAT Plus: Drug middlemen switch tactics, but the outcome is the same: high prices

Pharmalot Ed Silverman

STAT Plus: Dutch health minister won’t cover a Gilead cancer drug due to the cost

Pharmalot Ed Silverman

STAT Plus: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines

Pharmalot Ed Silverman and Damian Garde

STAT Plus: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs

Opinion

First Opinion Brian Finrow, Aleks Engel and Srinivas Akkaraju

STAT Plus: Drug developers navigating ‘biology’s century’ need a model. We made one

Biopharma R&D productivity has been in steady decline for at least three decades. Reversing this trend will require many interventions.

First Opinion

STAT Plus: Clearing the patent thicket: A pathway to faster generic drug approvals

First Opinion

STAT Plus: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs

Video

Pharmalot Alex Hogan and Ed Silverman

STAT Plus: Watch: Blockbuster drug Humira has new competition. Here’s why that matters

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition.

Pharma

STAT Plus: Watch: How do the new obesity drugs work?

Pharma

STAT Plus: Watch: This small-town pharmacy may be a model for more affordable drugs

All Coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA approves over-the-counter Narcan; J&J exits the race for the first RSV vaccine

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: WHO may add obesity drugs to essential medicines list; monkey shortage may delay drug development

advertisement

Biotech Betsy Ladyzhets

Under pressure, biotech and pharma grapple with how to take climate action

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations

Politics Sarah Owermohle

STAT Plus: Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?

Health Benedict Carey

STAT Plus: A half century after Prozac, a new generation of depression drugs is bringing hope to a long-stagnant field

Pharmalot Ed Silverman

STAT Plus: Ohio attorney general accuses pharmacy benefit managers of drug price fixing

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA proposes more rigorous cancer drug trials for accelerated approval; insurers not covering obesity meds for kids

Pharmalot Ed Silverman

STAT Plus: California judge deals GSK a setback as first Zantac lawsuit will now go to trial

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to deaths

Pharmalot Ed Silverman

STAT Plus: J&J loses a patent battle in India over a crucial tuberculosis drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty med costs

Pharmalot Ed Silverman

STAT Plus: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines

Politics Rachel Cohrs

Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug

Pharmalot Ed Silverman

STAT Plus: NIH rejects bid to cut a cancer drug’s price by sidestepping patents

Pharmalot Ed Silverman

STAT Plus: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax breaks in the semiconductor package

Politics Helen Branswell, Rachel Cohrs and Damian Garde

STAT Plus: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

Pharmalot Ed Silverman

STAT Plus: Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children disappoint

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research